This pilot study aims to identify predictors of response to intranasal ketamine treatment in patients with treatment-resistant depression.
Participants will give a sample of blood and undergo magnetic resonance imaging before and after a single intranasal ketamine treatment. Participants will subsequently receive a second intranasal ketamine treatment.
Compound Ketamine
Country United States of America
Visit trial
Status
Completed
Results Published
Start date
26 June 2019
End date
28 December 2020
Chance of happening
100%
Phase
Phase II
Phase III
Design
Open
Type
Interventional
Participants
9
Sex
All
Age
18- 65
Therapy
No
Trial Details
This pilot study aims to identify predictors of response to intranasal ketamine treatment in patients with treatment-resistant depression. Participants will give a sample of blood and undergo magnetic resonance imaging before and after a single intranasal ketamine treatment. Participants will subsequently receive a second intranasal ketamine treatment.NCT Number NCT04216888
Sponsors & Collaborators
Nathan Kline Institute for Psychiatric ResearchAt the Nathan Kline Institute for Psychiatric Research (NKI), investigators study the causes, treatment, prevention, and rehabilitation of severe and persistent mental illnesses.
Measures Used
Montgomery-Asberg Depression Rating ScaleA ten-item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders.